We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
Check what you need to do to sell cosmetic products in Great Britain.
Information on how to report a serious undesirable effect (SUE) or safeguarding issue for cosmetic products.
This independent report sets out recommendations to protect people who choose cosmetic surgery.
Safety leaflet on topical corticosteroids and withdrawal reactions to help patients and their carers to use these medicines safely.
How to submit a cosmetic product notification to the Office for Product Safety and Standards (OPSS).
We are seeking your views on what procedures should be in scope of the licensing scheme for non-surgical cosmetic procedures in England.
Forms for the notification of serious undesirable effects (SUEs) from cosmetic products in Great Britain.
People and businesses are invited to share their views on how to make non-surgical cosmetic procedures safer as thousands complain of ‘botched’ procedures.
Apply for a dermatological product to be considered by the Advisory Committee on Borderline Substances (ACBS).
Case study on the regulation of the providers of injectable cosmetic treatments in a rapidly growing market.
Information and advice on submitting a dermatological product to the Advisory Committee for Borderline Substances (ACBS).
How the MHRA makes decisions on when a product is a medical device (borderline products), and which risk class should apply to a medical device.
Information for local authorities, the police and others involved in enforcing the Botulinum Toxin and Cosmetic Fillers (Children) Act 2021.
Information for under 18s and their parents or guardians on the Botulinum Toxin and Cosmetic Fillers (Children) Act 2021.
Topical steroid products are safe and highly effective treatments for the management of a wide range of inflammatory skin diseases but have important risks, especially with prolonged use at high potency. In the coming months, as a result of regulatory...
Following MHRA approval of a clinical trial, early breast cancer patients on endocrine-based therapy can benefit from a study with camizestrant.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).